Nov 29, 2001 (CIDRAP News) The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.
(CIDRAP News) A new study commissioned by the US Department of Agriculture (USDA) indicates that the risk of bovine spongiform encephalopathy (BSE) occurring in the United States is extremely low, but USDA officials who released the study said they are considering taking steps to lower the risk further.
Dec 4, 2003 (CIDRAP News) Thousands of US Customs and Border Protection (CBP) officers will help the Food and Drug Administration (FDA) inspect imported food under an agreement signed yesterday, according to the FDA.
(CIDRAP News) A recent analysis of ground pork in grocery stores in five states showed that 4% of the samples contained enterococci with high-level resistance to gentamicin, an antibiotic used to treat enterococcal infections in humans. In addition, most Enterococcus faecium isolates were resistant to quinupristin-dalfopristin (Synercid), a streptogramin antibiotic used to treat infections caused by vancomycin-resistant E faecium.
(CIDRAP News) In view of the specter of bioterrorism, it's time to overhaul the hodgepodge of outdated, little-known, inconsistent state laws dealing with public health emergencies in the United States, an expert on the subject told a conference audience in Minneapolis yesterday.
(CIDRAP News) The Food and Drug Administration (FDA), citing a risk of serious infections with Enterobacter sakazakii, has recommended that milk-based powdered infant formulas not be used in neonatal intensive care units (NICUs) unless there is no alternative.
A ruling by the Food and Drug Administration on whether to stop the use of enrofloxacin in poultry because of concern about antimicrobial resistance is more than a year away, according to a hearing schedule laid out by an FDA official.
(CIDRAP News) The Food and Drug Administration (FDA) this week endorsed a widespread cosmetic procedure by approving the use of botulinum toxin type A to temporarily smooth frown lines between the eyebrows.